Morihiro Higashi

Dr. Morihiro Higashi


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2000 in Experimental Hematology
Verified
Journal Article
Closed access
YQYa-Wei Qiang
Ya-Wei Qiang
MKMotoo Kitagawa
Motoo Kitagawa
MHMorihiro Higashi
Morihiro Higashi
GIGenichiro Ishii
Genichiro Ishii
CMChikao Morimoto
Chikao Morimoto
KHKenichi Harigaya
Kenichi Harigaya

14 March 2022 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
MHMorihiro Higashi
Morihiro Higashi
SMShuji Momose
Shuji Momose
NTNatsuko Takayanagi
Natsuko Takayanagi
YTYuka Tanaka
Yuka Tanaka
TATomoe Anan
Tomoe Anan
JTJun-ichi Tamaru
Jun-ichi Tamaru
The tumor microenvironment (TME) is a critical regulator of the development of malignant lymphoma. Therapeutics targeting the TME, especially immune checkpoint molecules, are changing the treatment strategy for lymphoma. However, the overall response to these therapeutics for diffuse large B‐cell lymphoma (DLBCL) is modest and new targets of immunotherapy are needed. To find critical immune checkpoint molecules for DLBCL, we explored the prognostic impact of immune checkpoint molecules and their ligands using publicly available datasets of gene expression profiles. In silico analysis of three independent datasets (GSE117556, GSE10846, and GSE181063) revealed that DLBCL expressing CD24 had a poor prognosis and had a high frequency of MYC aberrations. Moreover, gene set enrichment analysis showed that the ‘MYC‐targets‐hallmark’ (false discovery rate [FDR] = 0.024) and ‘inflammatory‐response‐hallmark’ (FDR = 0.001) were enriched in CD24‐high and CD24‐low DLBCL, respectively. In addition, the expression of cell‐specific markers of various immune cells was higher in CD24‐low DLBCL than in CD24‐high DLBCL. CIBERSORT analysis of the datasets showed fewer macrophages in CD24‐high DLBCL than in CD24‐low DLBCL. Additionally, immunohistochemical analysis of 335 cases of DLBCL showed that few TME cells were found in CD24‐high DLBCL, although statistical differences were not observed. These data indicate that CD24 expression suppresses immune cell components of the TME in DLBCL, suggesting that CD24 may be a target for cancer immunotherapy in aggressive large B‐cell lymphoma.

28 December 2022 in The American Journal of Pathology
Verified
Journal Article
Closed access
TYTakahisa Yamashita
Takahisa Yamashita
MHMorihiro Higashi
Morihiro Higashi
HSHironori Sugiyama
Hironori Sugiyama
MMMakoto Morozumi
Makoto Morozumi
SMShuji Momose
Shuji Momose
JTJun-Ichi Tamaru
Jun-Ichi Tamaru

1 January 2017 in Journal of Clinical and Experimental Hematopathology
Verified
Journal Article
Open access
MTMichihide Tokuhira
Michihide Tokuhira
TTTakayuki Tabayashi
Takayuki Tabayashi
YTYuka Tanaka
Yuka Tanaka
YTYasuyuki Takahashi
Yasuyuki Takahashi
YKYuta Kimura
Yuta Kimura
MKMasahiro Kizaki
Masahiro Kizaki
Recently, attention has been focused on methotrexate-induced lymphoproliferative disease (MTX-LPD), and atypical phenotypes are occasionally documented. We encountered two patients with rheumatoid arthritis (RA) who were diagnosed with non-specific LPD (LPD-nos). Biopsy samples were not obtained during the initial examination when the LPD development was discovered, and the patients achieved a complete response after MTX cessation (case 1) or steroid pulse therapy (case 2). However, the tumors flared up 1.5 years later, and LPD-nos was determined following biopsies of the lymph node (LN, case 1) and liver (case 2). Prednisolone was subsequently administered instead of chemotherapy; however, multiple masses, including in the spine (case 1), and severe icterus with liver dysfunction (case 2) were exacerbated within a few months. Although the re-biopsy of LN proved the presence of HL and radiation followed by aggressive chemotherapy rescued the patient (case 1), the superficially accessible biopsy site was not found, and autopsy finally revealed HL (case 2). In both cases, the underlying pathogenesis along with the B symptoms and laboratory abnormalities suggested MTX-LPD, HL in particular. Therefore, even if the pathological diagnosis does not confirm the specific LPD subtype, the administration of aggressive chemotherapy should be considered if the LPD activity flares severely.

14 September 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
YKYouichi Kumagai
Youichi Kumagai
KTKaiyo Takubo
Kaiyo Takubo
KKKenro Kawada
Kenro Kawada
MOMasayuki Ohue
Masayuki Ohue
MHMorihiro Higashi
Morihiro Higashi
HIHideyuki Ishida
Hideyuki Ishida
This review outlines the process of the development of the endocytoscope (EC) with reference to previously reported studies including our own. The EC is an ultra-high-magnification endoscope capable of imaging at the cellular level. The esophagus is the most suitable site for EC observation because it is amenable to vital staining. The diagnosis of esophageal lesions using EC is based on nuclear density and nuclear abnormality, allowing biopsy histology to be omitted. The observation of nuclear abnormality requires a magnification of ×600 or higher using digital technology. Several staining methods have been proposed, but single staining with toluidine blue or methylene blue is most suitable because the contrast at the border of a cancerous area can be easily identified. A three-tier classification of esophageal lesions visualized by EC is proposed: Type 1 (non-cancerous), Type 2 (endocytoscopic borderline), and Type 3 (cancerous). Since characteristic EC images reflecting pathology can be obtained from non-cancerous esophageal lesions, a modified form of classification with four additional characteristic non-cancerous EC features has also been proposed. Recently, deep-learning AI for analysis of esophageal EC images has revealed that its diagnostic accuracy is comparable to that of expert pathologists.

28 August 2019 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
THTai Hato
Tai Hato
MYMasatoshi Yamaguchi
Masatoshi Yamaguchi
ASAto Sugiyama
Ato Sugiyama
KAKohei Aoki
Kohei Aoki
YIYoshiaki Inoue
Yoshiaki Inoue
MNMitsuo Nakayama
Mitsuo Nakayama
While calcification of thymoma is common, “eggshell” calcification is rare. We report a case of an eggshell calcified thymoma that “hatched” after 4 years of follow-up. Pathologically, it revealed that sarcoidosis accompanied this case of thymoma, which might cause in calcification. The patient was a 68-year-old female. A 20-mm anterior mediastinal nodule completely covered with calcification was noted in an annual health check-up. However, as the nodule did not change during 6 months of follow-up, she discontinued regular examinations. Four years later, an abnormality in her chest X-ray was noted again. The tumor grew outside the calcification to reach 63 mm. She underwent resection of this anterior mediastinal tumor. Pathologically, the tumor was diagnosed as thymoma of type B1 in the WHO classification. The histology of the tumor inside and outside of the calcification was not different, suggesting that the tumor grew from the inside of the calcification. The calcification was located within the fibrotic capsule of thymoma. Sarcoidosis also presented in her lung and mediastinal lymph nodes. Although the mechanism of calcification of the capsule was not clear, sarcoidosis might be related to this case because macrophage accumulation and altered lipid metabolism in sarcoidosis present with similar dystrophic calcification.